Skip to main content
Premium Trial:

Request an Annual Quote

RXi Posts Flat Q3 Net Loss

Premium

NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week reported its third-quarter financial results, posting a net loss essentially flat with last year as expenses held steady.

For the three-month period ended Sept. 30, RXi's net loss was $2.2 million, or $.17 a share, compared with $2.1 million, or $.30 a share, the year before.

Research and development spending in the quarter was $1.5 million, up slightly from expenses of $1.2 million a year ago. General and administrative costs, meanwhile, dipped to $2.5 million from $2.6 million.

At the end of the third quarter, RXi had cash, cash equivalents, and short-term investments totaling $10.1 million.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more